Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases

Characteristic

All patients

 

N(%)

No. of patients

50

Median age

48 (26-72 years)

< 40 years

12 (24%)

≥40 years

38 (76%)

Ethnicity

 

Caucasian

34 (68%)

African American

15 (30%)

Other

1 (2%)

Stage

N = 34

I

4 (12%)

II

17 (50%)

III

10 (29%)

IV

3 (9%)

IHC subtype

N = 43

HR+/HER2-

12 (28%)

HR-/HER2- (TN)

19 (44%)

HER2+

12 (28%)

Systemic therapy for primary BC

 

Chemotherapy

44/48 (92%)

Endocrine therapy (for HR+/HER2-)

6/11 (55%)

Trastuzumab (for HER2+)

2/12 (17%)

Systemic therapy for metastatic BC

 

Chemotherapy

28/38 (74%)

Endocrine therapy (for HR+/HER2-)

7/10 (70%)

Her2-directed therapy (for HER2+)

6/9 (67%)

BCBM therapy

N = 47

Cranial XRT

25 (53%)

Radiosurgery

4 (9%)